1Jonker DJ, O' Callaghan C J, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer[ J]. N Engl J Med, 2007, 357 (20) : 2040-2048.
2Zhang W, Gordon M, Sehuhheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epi- dermal growth factor receptor-expressing metastatic eolorectal canc- er patients trested with single-agent cetuximab [ J ]. J Clin Oncol, 2007,25 (24) :3712-3718.
3Zhang W, Winder T, Ning Y, et al. A let-7 microRNA-binding site polymorphism in 3 '-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy [ J ]. Ann Oncol, 2011, 22(1) : 104-109.
4Dahan L, Norguet E, Etienne-Grimaldi MC, et al. Pharmaeoge- netic profiling and cetuximab outcome in patients with advanced colorectal cancer[ J]. BMC Cancer, 2011, 11:496.
5Stoehlmacher-Williams J, Obermann L, Ehninger G, et al. Poly- morphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC)[J]. Anticancer Res. 2012, 32 (2) :421-425.
6Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a random- ized triM[J]. JAMA, 2003, 290(16) : 2149-2158.
7Sanford M, Scott LJ. Gefitinib : a review of its use in the treatment of locally advanced metastatic non-small cell lung cancer [J]. Drugs, 2009, 69(16): 2303-2328.
8Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity [J]. Pharmacogenomics J, 2009, 10( 1 ) : 59-68.
9Ma F, Sun T, Shi Y, et al. Polymorphisms of EGFR predict clini- cal outcome in advanced non-small-cell lung cancer patients trea- ted with gefitinib[J]. Lung Cancer, 2009, 66( 1 ) : 114-119.
10Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small cell lung cancer patients treated with gefitinib [ J ]. Pharmacog- enomics J, 2008, 8(2) : 129-138.
7Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burden of cancer in2008:GLOBOCAN2008[J].Int J Cancer,2010,127(12):2893.
8Cappuzzo F,Hirsch FR,Rossi E,et al.Epidermal grow-th factor receptor gene and protein and gefitinib sensitivi-ty in non-small-cell lung cancer[J].J Nat Cancer Insti-tute,2005,97(9):643.
9Vincent MD,Kuruvilla MS,Leighl NB,et al.Biomark-ers that currently affect clinical practice:EGFR,ALK,MET,KRAS[J].Cur Oncol,2012,19(Suppl1):S33.
10Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(7153):561.
